Resultado de búsqueda
10 de ene. de 2024 · Elis announces the signing of an agreement for the acquisition of Moderna Holding BV in the Netherlands. Saint-Cloud, 10 January 2024 – Elis, the global leader in circular services at work, today announces the signing of an agreement to acquire 100% of Moderna Holding BV (« Moderna ») in the Netherlands.The closing of the transaction is expected to occur before the end of Q1 2024, subject ...
Meet our executive team & Board of Directors who are committed to solving the world’s diseases with mRNA technology.
At Moderna, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
12 de dic. de 2023 · CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The Company has decided ...
8 de ene. de 2024 · Jamey Mock, Chief Financial Officer of Moderna, will present an update on the Company and its pipeline of mRNA development programs on Monday, January 8 th, 2024, at 3:45 p.m. PT/6:45 p.m. ET at the 42 nd Annual J.P. Morgan Healthcare Conference. A live webcast of both the presentation and the question-and-answer session will be available under ...
17 de nov. de 2020 · The chancellor, Rishi Sunak, has refused to disclose whether he will profit from a surge in the share price of the Covid-19 vaccine manufacturer Moderna, one of the biggest investments held by the ...
19 de abr. de 2024 · The Vanguard Group is one of Moderna's top shareholders, holding shares of the company in some of its top mutual funds including the ... Moderna had a 48% share of the U.S. market for the COVID-19 ...
